

21 December 2019

Helsinki, Finland

Press Release – Important milestones in 2019 and setting the scene for 2020

LS CancerDiag looks back on the year marked by the achievement of major milestones. 2019 started off with obtaining the CE mark for DiagMMR® as *in vitro* diagnostic medical device (IVD MD), enabling commercialization in Europe. Shortly after, LS CancerDiag entered into distribution agreements in its home market covering virtually the whole of Finland. And soon the next milestone came around the corner with the first sales!

However, that only marks the beginning of the next stage and LS CancerDiag is poised to conquer the European market and the rest of the world with its innovative predictive DiagMMR® test. The company has attended events and presented on important stages across Europe, including the Healthtech Investment Forum and Biotech in Europe Forum (Basel, Switzerland), Frontiers Health (Berlin, Germany), DxPx Conference (Düsseldorf, Germany), Slush (Helsinki, Finland), NOME Annual Meeting (Copenhagen, Denmark), and Tech Tour Contest Final (Essen, Germany).

LS CancerDiag has successfully applied to the InvestHorizon Accelerator and has also received the Seal of Excellence from the European Commission in the EIC Accelerator (formerly SME Instrument), where DiagMMR® was scored as a high-quality project proposal in a highly competitive evaluation process.

This all follows 2018, which had some highlights of its own, such as the completion of the clinical validation, and the patents granted in the US and Canada, joining other key markets in the patent portfolio of the company now encompassing 28 countries, including the EU, Russia, China, and Japan.

Looking ahead, 2020 promises to be another memorable year. LS CancerDiag will kick off the new decade with a bang at the Startup Health Festival in San Francisco, followed by market exploration efforts and connecting with key opinion leaders in the healthcare sector across the US. And in Europe, international pilot operations will be initiated in a first step towards scale-up across the continent.

About LS CancerDiag Ltd

LS CancerDiag is committed to reducing cancer mortality rates with a simple and accurate diagnostic method that detects an inherited cancer-causing condition prior to cancer and enables preventive and personalized care. Lynch syndrome (previously known as Hereditary Non-Polyposis Colorectal Cancer; HNPCC) is the main cause of hereditary colorectal cancers, but it is also linked to endometrial cancer and various other types of tumors. With its high prevalence in the world's population and the currently very low diagnosis rates, there are millions of people with Lynch syndrome without being aware of it. The groundbreaking DiagMMR® assay is an easy functional test that can be used for diagnosis of MMR deficiency, the key characteristic of Lynch syndrome. The company mission is to save lives through an innovation that dramatically simplifies diagnostics of Lynch syndrome by delivering predictive and accurate results globally with a fast, unique and cost-efficient method.

Contact information

Philippe Arnez, Chief Business Officer
philippe.arnez@lscancerdiag.com

LS CancerDiag Ltd 
@LSCancerDiag 

<http://www.lscancerdiag.com>